Form 4: United Therapeutics CFO exercises, sells shares

CFO James Edgemond exercised 21,000 options at $146.03 and sold all resulting shares at ~$464–$476 under a 10b5-1 plan, maintaining 8,118 direct shares and 21,517 options outstanding.

Summary

• On 11/17/2025, CFO and Treasurer James Edgemond executed a pre-set Rule 10b5-1 trading plan adopted on 08/05/2025.
• Exercised 21,000 stock options at an exercise price of $146.03 (two tranches: 10,688 and 10,312).
• Sold 21,000 shares in multiple trades with weighted average prices ranging from $464.3842 to $476.4706; trade price ranges spanned $463.67 to $476.58.
• Direct beneficial ownership remains 8,118 common shares after the transactions.
• 21,517 stock options remain beneficially owned following the reported transactions.
• Option grants were exercisable since 03/15/2020 and have an expiration date of 03/15/2027.
• Form signed by attorney-in-fact (John S. Hess, Jr.) on 11/18/2025.

Sentiment

Score: 5

Explanation: Neutral to mildly negative sentiment: sizeable insider sale balanced by pre-set 10b5-1 plan, no net change in direct share holdings, and substantial remaining options.

Positives

• Transactions executed under a Rule 10b5-1 plan adopted on 08/05/2025, mitigating concerns about trade timing.
• Direct share ownership unchanged at 8,118 shares after the activity, indicating no net reduction in core holdings.
• Continued alignment via 21,517 remaining stock options beneficially owned.

Negatives

• Large insider sale of 21,000 shares may be perceived negatively by some investors.
• Exercise-and-immediate-sale indicates limited incremental personal capital commitment at present prices.

Future Outlook

No forward-looking statements or guidance provided; activity reflects pre-planned personal trading under a Rule 10b5-1 plan.

Management Comments

• Transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on August 5, 2025.
• Sales were executed in multiple trades within specified price ranges; weighted average prices are reported and full trade details are available upon request.

Industry Context

Pre-planned 10b5-1 insider sales are common among large-cap biotech executives for diversification and do not, by themselves, indicate changes in business fundamentals.

Comparison to Industry Standards

• Use of Rule 10b5-1 plans is standard among peers such as Regeneron, Gilead, and Biogen to systematize insider selling and reduce timing concerns.
• Exercising deep-in-the-money options and selling shares near-term ahead of option expirations is a typical practice to manage concentration and tax obligations.
• Maintaining a continuing equity stake post-sale aligns with governance expectations for executive-shareholder alignment.

Stakeholder Impact

• Shareholders: insider sale under a 10b5-1 plan may influence sentiment but direct holdings remain at 8,118 shares.
• Employees: no impact disclosed.
• Customers and suppliers: no operational impact indicated.
• Creditors: no changes to financial position disclosed.

Next Steps

• No further actions disclosed.

Key Dates

Keywords

United Therapeutics, UTHR, Form 4, insider transaction, Rule 10b5-1, stock option exercise, insider selling, James Edgemond, CFO, biotechnology